8-K: Leap Therapeutics Announces Positive Clinical Trial Updates and $40 Million Private Placement

Leap Therapeutics reported encouraging clinical trial results for its DKN-01 drug and completed a $40 million private placement to fund operations into 2026.

Summary

• Leap Therapeutics announced its financial results for the second quarter of 2024, highlighting progress in its clinical trials and a recent private placement.
• The company's DKN-01 drug showed an overall response rate of 33% in all evaluable patients and 38% in patients with left-sided colorectal cancer in the DeFianCe study.
• The randomized controlled Part B of the DeFianCe study has been expanded to 180 patients, with enrollment expected to be completed by the end of September 2024 and data expected in mid-2025.
• Patient follow-up is ongoing in the DisTinGuish study, with initial data expected in Q4 2024 or early 2025.
• Leap Therapeutics completed a $40 million private placement with new and existing investors, including Gilead Sciences, Inc.
• The company's net loss for the second quarter of 2024 was $20.4 million, compared to $13.4 million for the same period in 2023, primarily due to increased research and development expenses.
• Research and development expenses increased to $17.9 million in Q2 2024 from $11.1 million in Q2 2023, driven by higher clinical trial costs.
• Cash and cash equivalents totaled $78.5 million as of June 30, 2024, which is expected to fund operations into the second quarter of 2026.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a successful capital raise, indicating a strong outlook for the company. The increased net loss is a concern, but the overall tone is optimistic.

Positives

• The DKN-01 drug showed promising results with a 33% overall response rate and a 38% response rate in left-sided CRC patients.
• The disease control rate was very high at 93% overall and 100% in left-sided CRC patients.
• The $40 million private placement provides significant funding to support ongoing clinical trials and operations.
• The company has a cash runway into the second quarter of 2026, providing financial stability.
• The expansion of the DeFianCe study to 180 patients indicates strong confidence in the drug's potential.

Negatives

• The company's net loss increased to $20.4 million in Q2 2024 from $13.4 million in Q2 2023.
• Research and development expenses increased significantly to $17.9 million in Q2 2024 from $11.1 million in Q2 2023.

Risks

• The company's clinical trials may not be successful, and the results may not lead to regulatory approvals.
• The company may face challenges in enrolling patients in its clinical trials.
• The company's financial results may be impacted by fluctuations in currency rates and interest rates.
• The company's cash runway is dependent on the successful execution of its clinical trials and business plan.
• There is a risk that the company may not be able to maintain its strategic partnerships.

Future Outlook

The company expects to complete enrollment in Part B of the DeFianCe study by the end of September 2024, with data expected in mid-2025, and initial data from Part C of the DisTinGuish study is expected in Q4 2024 or early 2025. The company's cash is expected to fund operations into the second quarter of 2026.

Management Comments

• With the momentum provided by our $40 million private placement, we are positioned to achieve our critical company milestones, said Douglas E. Onsi, President and Chief Executive Officer of Leap.
• We have executed well on our two DKN-01 randomized controlled trials and on preparatory activities for registrational studies.
• We look forward to sharing initial data from both randomized controlled studies over the next 12 months as we strive to deliver new treatments for patients fighting against cancer.

Industry Context

Leap Therapeutics is operating in the competitive biotechnology sector, focusing on targeted and immuno-oncology therapeutics. The company's progress in clinical trials and its ability to secure funding are critical for its success in this space. The focus on DKN-01 for colorectal and gastroesophageal cancers aligns with the need for new treatments in these areas.

Comparison to Industry Standards

• The reported ORR of 33% and 38% in the DeFianCe study is promising compared to standard second-line treatments for advanced colorectal cancer, which often have lower response rates.
• Companies like Amgen and Eli Lilly have similar programs in oncology, but the specific focus on DKK1 inhibition with DKN-01 is a differentiator for Leap.
• The expansion of the DeFianCe study to 180 patients is a positive sign, as it indicates confidence in the drug's potential and a commitment to robust clinical data.
• The $40 million private placement is a significant achievement, as many biotech companies struggle to secure funding for their clinical programs. This funding positions Leap well compared to peers with less financial stability.

Stakeholder Impact

• Shareholders will likely view the positive clinical trial results and successful private placement favorably.
• Employees may feel more secure with the extended cash runway and progress in clinical trials.
• Patients may benefit from the potential development of new cancer treatments.
• Investors are likely to be encouraged by the company's progress and financial stability.

Next Steps

• Complete enrollment in Part B of the DeFianCe study by the end of September 2024.
• Report data from Part B of the DeFianCe study in mid-2025.
• Report initial data from Part C of the DisTinGuish study in Q4 2024 or early 2025.

Key Dates

Keywords

DKN-01, colorectal cancer, CRC, gastroesophageal junction cancer, GEJ, clinical trials, oncology, biotechnology, private placement, research and development, LPTX